Vor Biopharma Inc. (VOR)
NASDAQ: VOR
· Real-Time Price · USD
0.67
0.01 (1.36%)
At close: May 02, 2025, 3:59 PM
0.66
-1.27%
After-hours: May 02, 2025, 05:23 PM EDT
Company Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.
It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.
The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers.
Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Vor Biopharma Inc.
| Country | United States |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Dr. Robert Ang M.B.A., M.D., MBBS |
Contact Details
Address: 100 Cambridgepark Drive Cambridge, Massachusetts United States | |
| Website | https://www.vorbio.com |
Stock Details
| Ticker Symbol | VOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001817229 |
| CUSIP Number | 929033108 |
| ISIN Number | US9290331084 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | President, Chief Executive Officer & Director |
| Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer & Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | DEFR14A | Filing |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 08, 2025 | ARS | Filing |
| Apr 08, 2025 | DEFA14A | Filing |
| Apr 08, 2025 | DEF 14A | Filing |
| Apr 03, 2025 | 8-K | Current Report |
| Mar 28, 2025 | PRE 14A | Filing |
| Mar 20, 2025 | S-8 | Filing |
| Mar 20, 2025 | S-3 | Filing |
| Mar 20, 2025 | 10-K | Annual Report |